IRIS
Narcisi, Alessandra
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 3.388
NA - Nord America 2.418
SA - Sud America 1.071
EU - Europa 619
AF - Africa 114
Continente sconosciuto - Info sul continente non disponibili 6
OC - Oceania 3
AN - Antartide 1
Totale 7.620
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.302
SG - Singapore 1.983
BR - Brasile 852
VN - Vietnam 540
CN - Cina 515
IT - Italia 104
AR - Argentina 96
HK - Hong Kong 78
FI - Finlandia 73
IE - Irlanda 66
IN - India 60
FR - Francia 56
GB - Regno Unito 54
DE - Germania 51
CA - Canada 49
EC - Ecuador 44
MX - Messico 44
ID - Indonesia 35
RU - Federazione Russa 33
BD - Bangladesh 29
NL - Olanda 29
NG - Nigeria 27
ZA - Sudafrica 27
SE - Svezia 24
CO - Colombia 22
PL - Polonia 22
BE - Belgio 21
ES - Italia 20
UA - Ucraina 20
IQ - Iraq 19
PK - Pakistan 19
JP - Giappone 18
TR - Turchia 17
MA - Marocco 14
PY - Paraguay 14
VE - Venezuela 13
TN - Tunisia 11
CL - Cile 9
PE - Perù 9
DZ - Algeria 8
KE - Kenya 8
EG - Egitto 6
MY - Malesia 6
UZ - Uzbekistan 6
XK - ???statistics.table.value.countryCode.XK??? 6
AT - Austria 5
DO - Repubblica Dominicana 5
KG - Kirghizistan 5
KZ - Kazakistan 5
NP - Nepal 5
PH - Filippine 5
SA - Arabia Saudita 5
UY - Uruguay 5
AL - Albania 4
BO - Bolivia 4
CZ - Repubblica Ceca 4
ET - Etiopia 4
HN - Honduras 4
IL - Israele 4
LT - Lituania 4
LV - Lettonia 4
OM - Oman 4
PS - Palestinian Territory 4
TH - Thailandia 4
AE - Emirati Arabi Uniti 3
AU - Australia 3
AZ - Azerbaigian 3
BH - Bahrain 3
EE - Estonia 3
GE - Georgia 3
HU - Ungheria 3
NI - Nicaragua 3
PA - Panama 3
RO - Romania 3
SR - Suriname 3
BG - Bulgaria 2
BY - Bielorussia 2
CR - Costa Rica 2
KW - Kuwait 2
LB - Libano 2
LY - Libia 2
MT - Malta 2
QA - Qatar 2
SK - Slovacchia (Repubblica Slovacca) 2
SN - Senegal 2
TT - Trinidad e Tobago 2
AO - Angola 1
AQ - Antartide 1
BA - Bosnia-Erzegovina 1
BN - Brunei Darussalam 1
CH - Svizzera 1
DK - Danimarca 1
GA - Gabon 1
GN - Guinea 1
GP - Guadalupe 1
GT - Guatemala 1
JM - Giamaica 1
JO - Giordania 1
LK - Sri Lanka 1
LU - Lussemburgo 1
Totale 7.612
Salva come PNG Salva come JPEG
Città #
Singapore 647
Ashburn 347
San Jose 267
Chandler 245
Shanghai 204
Ho Chi Minh City 188
Dallas 169
The Dalles 167
Beijing 150
Hanoi 99
Boardman 89
Wilmington 86
Hong Kong 76
Helsinki 73
New York 69
São Paulo 69
Dublin 65
Los Angeles 46
San Mateo 45
Milan 36
Ann Arbor 34
Lawrence 34
Princeton 34
Santa Clara 33
Haiphong 31
Benin City 27
Da Nang 26
Paris 26
Rio de Janeiro 26
Brussels 21
Brooklyn 19
Mexico City 19
Phoenix 18
Belo Horizonte 17
Orem 17
Tokyo 17
Guayaquil 16
Hải Dương 16
London 16
Seattle 16
Warsaw 16
Amsterdam 15
Can Tho 15
Johannesburg 15
Leawood 14
Montreal 14
Assago 12
Buenos Aires 12
Chennai 12
Curitiba 12
Quito 12
Salvador 12
Chicago 11
Frankfurt am Main 11
Brasília 10
Council Bluffs 10
Fairfield 10
Ninh Bình 10
Toronto 9
Dronten 8
Falkenstein 8
Jakarta 8
Mumbai 8
Nairobi 8
Poplar 8
Porto Alegre 8
Sorocaba 8
São Bernardo do Campo 8
Thái Bình 8
Bauru 7
Boston 7
Campinas 7
Charlotte 7
Dhaka 7
Goiânia 7
Lima 7
Munich 7
Phủ Lý 7
Recife 7
San Francisco 7
Teresina 7
Tây Ninh 7
Uberlândia 7
Anápolis 6
Atlanta 6
Baghdad 6
Biên Hòa 6
Bắc Giang 6
Caracas 6
Ha Long 6
Istanbul 6
New Delhi 6
Osasco 6
Sumaré 6
Tashkent 6
Tunis 6
Woodbridge 6
Asunción 5
Belém 5
Cape Town 5
Totale 4.109
Salva come PNG Salva come JPEG
Nome #
Melanoma in Adolescents and Young Adults (AYAs): An Italian Multi-Centric Retrospective Experience 201
Chronic Hand Eczema (CHE): A Narrative Review 109
Brodalumab: a new way to inhibit IL-17 in psoriasis 108
A fatal case of COVID-19 infection presenting with an erythema multiforme-like eruption and fever 94
Specific Infiltrate of Hodgkin Lymphoma at Site of Cellulitis Mimicking Secondary Cutaneous Involvement 90
Programmed cell death in the skin 89
Anti-IL17 and anti-IL23 biologic drugs for scalp psoriasis: A single-center retrospective comparative study 84
Use of biological drugs in patients with psoriasis and psoriatic arthritis in Italy: Results from the PSONG survey 83
Clinical course of COVID-19 in 41 patients with immune-mediated inflammatory diseases: Experience from humanitas center, Milan 80
Biologic therapies for plaque type psoriasis in patients with previous malignant cancer: long-term safety in a single- center real-life population 79
Apremilast for the treatment of palmo-plantar non-pustular psoriasis: A real-life single-center retrospective study 79
Long-term treatment with adalimumab in psoriatic arthritis: serum adalimumab concentration, immunogenicity and the link with clinical response 77
Real-life Effectiveness and Safety of Risankizumab in Moderate-to-severe Plaque Psoriasis: A 40-week Multicentric Retrospective Study 76
Psychiatric comorbidity and suicidal ideation in psoriasis, melanoma and allergic disorders 76
S100A8/A9 in psoriatic plaques from patients with psoriatic arthritis 74
A real-world economic analysis of biologic therapies for moderate-to-severe plaque psoriasis in Italy: results of the CANOVA observational longitudinal study 74
Long-term safety and efficacy of adalimumab in psoriasis: a multicentric study focused on infections (connecting study) 73
Drug survival of IL-12/23, IL-17 and IL-23 inhibitors for moderate-to-severe plaque psoriasis: a retrospective multicenter real-world experience on 5932 treatment courses – IL PSO (Italian landscape psoriasis) 71
Complicated coronavirus disease 2019 (COVID-19) in a psoriatic patient treated with ixekizumab 71
Reorganization of a Northern Italy dermatology department during the COVID-19 pandemic: is it temporary or the beginning of a new era in dermatology? 70
25-Hydroxyvitamin D serum levels and melanoma risk: a case-control study and evidence synthesis of clinical epidemiological studies 70
Long-term safety of etanercept in psoriasis: Retrospective study focused on infections 67
A severe psoriasis flare after COVID-19 treated with risankizumab: complete skin clearance after 16 weeks 66
Measuring psoriatic disease in clinical practice. An expert opinion position paper 66
noveaux horizon therapeutiques pour le prurit dermatologique au delà de la dermatite atopique: role de i-modulia 65
Generalized pustular psoriasis flare in a patient affected by plaque psoriasis after BNT162b2 mRNA COVID-19 vaccine, successfully treated with risankizumab 64
Diagnostic imaging: Listening in to skin disease 64
Impact of delay in follow-up due to COVID-19 pandemic on skin cancer progression: a real-life experience from an Italian hub hospital 63
Palmar nodules in a young woman with ulcerative colitis and enteropathic arthritis 63
Non-complicated evolution of COVID-19 infection in a patient with psoriasis and psoriatic arthritis during treatment with adalimumab 63
Effects of TNF-α inhibition on pre-clinical enthesitis: observational study on 49 psoriatic patients 63
A 3-Year Multicentric Study on Switching from Ustekinumab to Guselkumab in Partial Responders with Psoriasis—IL PSO (Italian Landscape Psoriasis) 61
Concomitant Pyoderma Gangrenosum-like and Amicrobial Pustulosis of the Folds: a Case Report 61
A risankizumab super responder profile identified by long-term real-life observation-IL PSO (ITALIAN LANDSCAPE PSORIASIS) 60
TP63 and TP73 in cancer, an unresolved "family" puzzle of complexity, redundancy and hierarchy. 59
Real-Life Effectiveness and Safety of Risankizumab in 131 Patients Affected by Moderate-to-Severe Plaque Psoriasis: A 52-Week Retrospective Study 58
Suicide risk and psychiatric comorbidity in patients with psoriasis 55
Noninvasive Assessment and Management of Folliculitis Decalvans by Trichoscopy and Reflectance Confocal Microscopy 54
An 18-year follow-up of a case of D-penicillamine-induced Elastosis perforans serpiginosa 54
Real-life effectiveness of tildrakizumab in chronic plaque psoriasis: A 52-week multicentre retrospective study-IL PSO (Italian landscape psoriasis) 53
Urticarial rash in autoinflammatory syndromes 52
Real-Life Effectiveness and Safety of Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: A Single-Center 16-Week Study 51
Long-term effectiveness and tolerability of apremilast in patients with moderate-to-severe plaque psoriasis: A 5-year multicentre retrospective study-IL PSO (Italian landscape psoriasis) 51
Long-Term Effectiveness and Safety of Ixekizumab for the Treatment of Moderate-to-Severe Plaque Psoriasis: A Five-Year Multicenter Retrospective Study—IL PSO (Italian Landscape Psoriasis) 50
Brodalumab for the treatment of plaque psoriasis in a real-life setting: a 3 years multicenter retrospective study-IL PSO (Italian landscape psoriasis) 50
Effectiveness and safety of bimekizumab for the treatment of plaque psoriasis: a real-life multicenter study-IL PSO (Italian landscape psoriasis) 49
Bullous vasculitis associated with Streptococcus pyogenes sepsis 49
Real-world evidence of biologic treatments in moderate-severe psoriasis in Italy: Results of the CANOVA (EffeCtiveness of biologic treAtmeNts for plaque psOriasis in Italy: An obserVAtional longitudinal study of real-life clinical practice) study 49
Cutaneous toxicity of CAR T-cell therapy: Case report of a bullous life-threatening reaction 48
Anti-IL-23 and anti-IL-17 drugs for the treatment of non-pustular palmoplantar psoriasis: a real-life retrospective study 48
Pregnancy outcome of a patient treated with upadacitinib for severe atopic dermatitis 47
Practical Use of Upadacitinib in Patients with Severe Atopic Dermatitis in a Real-World Setting: A Systematic Review 47
Biologics for the Treatment of Severe Acrodermatitis Continua of Hallopeau: Report of Two Cases Successfully Treated with Ixekizumab and Ustekinumab 47
Upadacitinib 30 mg for the optimal management of moderate-to-severe atopic dermatitis: a 52-week single-center real-world study 47
What Can IBD Specialists Learn from IL-23 Trials in Dermatology? 46
A case of lichen amyloidosus treated with acitretin 45
Fingertip dermatitis: a spy for psoriasis 45
Safety of anti-IL-23 drugs in patients with moderate-to-severe plaque psoriasis and previous tuberculosis infection: a monocentric retrospective study 44
Arrhythmias and other cardiovascular diseases in young patients (<40 years) with moderate/severe atopic dermatitis: A multicentric study in northern Italy 44
Real-life effectiveness and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: A 104-week multicenter retrospective study – IL PSO (ITALIAN LANDSCAPE PSORIASIS) 43
A Case of Ketron-Goodman Disease 43
Anti-interleukin-17 and anti-interleukin-23 biologic drugs for genital psoriasis: a single-center retrospective comparative study 42
Allergy to nickel: first results on patients administered with an oral hyposensitization therapy 42
Skin cancers: how to balance the risks and benefits of surgery during COVID-19 pandemic (a Northern Italy single-center experience) 42
Real-life Effectiveness and Safety of Guselkumab in Moderate-to-Severe Plaque Psoriasis: A 104-Week Retrospective Single-Center Study 42
An unusual case of annular bollous eruption of the inguinal folds 41
Tralokinumab rapidly improves subjective symptoms and quality of life in patients with moderate-to-severe atopic dermatitis: a real-life 16-week experience 41
Effectiveness and safety of upadacitinib for moderate‐to‐severe atopic dermatitis in a real‐world setting: A 52‐week retrospective study 41
Daily Patient's Relief From Pruritus and Sleep Disturbance Over One-Month Treatment with Upadacitinib in Patients with Moderate-to-Severe Atopic Dermatitis: A Multicenter Prospective Study 41
Safety of Biologic Therapies in Patients with Moderate-to-Severe Plaque Psoriasis and Concomitant Viral Hepatitis: A Monocentric Retrospective Study 41
Effectiveness of risankizumab in plaque psoriasis with involvement of difficult-to-treat areas: a real-world experience from two referral centers 41
Disseminated Superficial Porokeratosis with Dermal Amyloid Deposits 40
Pembrolizumab-induced plaque psoriasis successfully treated with risankizumab in a patient with stage IV cutaneous melanoma 40
Management of Patients Affected by Moderate-to-Severe Atopic Dermatitis with JAK Inhibitors in Real-World Clinical Practice: An Italian Delphi Consensus 39
A case of periocular contact dermatitis caused by cypress allergy 39
Comparative effectiveness of tildrakizumab 200 mg versus tildrakizumab 100 mg in psoriatic patients with high disease burden or above 90 kg of body weight: a 16-week multicenter retrospective study – IL PSO (Italian landscape psoriasis) 39
Dupilumab for the treatment of atopic dermatitis of the elderly: a real-life 52-week experience 39
Intra-Class Switch Among IL-23 Inhibitors for Plaque Psoriasis: Is It Worth It? 39
Anti-IL-17/23 Drugs for the Treatment of Moderate-to-Severe Hidradenitis Suppurativa in Patients With Concomitant Psoriasis: A Multicenter Retrospective Study 39
Risankizumab for the treatment of genital psoriasis: A 1-year, real-world experience 38
Topical Pharmacological Treatment of Actinic Keratoses: Focus on Tirbanibulin 1% Ointment 38
Autoreactivity to self-antigens LL37 and ADAMTSL5 influences the clinical response to risankizumab in psoriatic patients 38
A Multidisciplinary Approach Is Beneficial in Atopic Dermatitis 38
Clinical outcomes and management of JAK inhibitor-associated acne in patients with moderate-to-severe atopic dermatitis undergoing upadacitinib: A multicenter retrospective study 38
Angiomatoid lesions (leukocytoclastic vasculitis) as paraneoplastic manifestations of multiple myeloma IgA λ 37
An updated safety review of Hidradenitis Suppurativa treatment options 37
Cutaneous hypersensitivity to gluten 37
Real-life effectiveness and safety of dupilumab in adolescents with atopic dermatitis: a 52-week single-center retrospective study 37
Atypical facial pustular folliculitis by Klebsiella pneumoniae: a case report 37
Apremilast for the treatment of pustular psoriasis induced by neoadjuvant ifosfamide + etoposide chemotherapy for Ewing Sarcoma: a case report 37
Successful use of tralokinumab for the treatment of atopic dermatitis on the genitals 36
A case of pseudoepitheliomatous hyperplasia to tattoos 36
Upadacitinib for the treatment of atopic dermatitis in the elderly: an Italian case series of seven patients 36
Sub-erythrodermic psoriasis successfully treated with bimekizumab: A case report 36
Optimizing Tildrakizumab Dosing in Psoriasis: A 52-Week Multicenter Retrospective Study Comparing 100 mg and 200 mg-IL PSO (Italian Landscape Psoriasis) 36
Risk Assessment in Atopic Dermatitis: Guidance from a Multidisciplinary Expert Panel 35
The impact of biologic therapy for moderate-to-severe psoriasis on the immune responses to SARS-CoV-2 infection and vaccination 35
Drug Survival of Upadacitinib and Predicting Factors of Discontinuation in Adult Patients Affected by Moderate-to-Severe Atopic Dermatitis: An Italian Multicenter Analysis 35
Real-World Effectiveness and Safety of Upadacitinib and Abrocitinib in Moderate-to-Severe Atopic Dermatitis: A 52-Week Retrospective Study 35
CD63 cell expression detected by flow-cytometric determination of basophil activation in allergic patients 35
Totale 5.477
Salva come PNG Salva come JPEG
Categoria #
all - tutte 39.500
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 39.500
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202136 0 0 0 0 0 0 0 0 0 19 0 17
2021/2022154 2 0 5 31 1 0 9 21 13 17 46 9
2022/2023609 82 48 46 87 59 45 1 48 99 47 41 6
2023/2024623 25 49 126 27 15 60 60 66 16 20 64 95
2024/20251.333 15 22 19 18 8 111 94 68 170 242 215 351
2025/20264.921 689 407 537 854 297 228 1.079 319 305 206 0 0
Totale 7.798